AB Science annonce la publication de l’étude clinique pivot de phase 3 avec le masitinib dans la maladie d’Alzheimer dans la revue Alzheimer's Research & Therapy
28 févr. 2023 02h03 HE
|
AB Science
COMMUNIQUE DE PRESSE PUBLICATION DE L'ETUDE CLINIQUE PIVOT DE PHASE 3 AVEC LE MASITINIB DANS LA MALADIE D'ALZHEIMER DANS LA REVUE ALZHEIMER'S RESEARCH & THERAPY Paris, 28 février 2023, 8h AB...
AB Science announced the publication of the masitinib pivotal phase 3 clinical trial in Alzheimer’s Disease in the journal Alzheimer's Research & Therapy
28 févr. 2023 02h03 HE
|
AB Science
PRESS RELEASE PUBLICATION OF THE MASITINIB PIVOTAL PHASE 3 CLINICAL TRIAL IN ALZHEIMER'S DISEASE IN THE JOURNAL ALZHEIMER'S RESEARCH & THERAPY Paris, 28 February, 2023, 8am CET ...
Alzheimer's Disease Diagnostics and Therapeutics Global Market Report 2023: Increasing Use of Biomarkers for Diagnosis Drives Growth
17 févr. 2023 10h38 HE
|
Research and Markets
Dublin, Feb. 17, 2023 (GLOBE NEWSWIRE) -- The "Alzheimer's disease diagnostics and therapeutics Market, by Product, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030"...
IGC Reports Financial Results for Third Fiscal Quarter Ended Dec. 31, 2022
14 févr. 2023 19h41 HE
|
INDIA GLOBALIZATION CAPITAL INC.
POTOMAC, Md., Feb. 14, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (dba IGC, Inc.) (NYSE American: IGC) (“IGC” or the “Company”) today reported its third fiscal...
IGC to be Featured in Feb. 10 Radius Research Investor Webinar
08 févr. 2023 08h30 HE
|
INDIA GLOBALIZATION CAPITAL INC.
POTOMAC, Md., Feb. 08, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces that Ram Mukunda, CEO, and Claudia...
IGC Receives No Objection Letter from Health Canada
04 janv. 2023 08h00 HE
|
INDIA GLOBALIZATION CAPITAL INC.
POTOMAC, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces it has received a no objection...
AB Science a reçu l’approbation de la Food and Drug Administration (FDA) américaine pour initier une étude confirmatoire de phase 3 avec le masitinib dans le traitement de la maladie d’Alzheimer
21 nov. 2022 12h09 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE A RECU L’APPROBATION DE LA FOOD AND DRUG ADMINISTRATION (FDA) AMÉRICAINE POUR INITIER UNE ÉTUDE CONFIRMATOIRE DE PHASE 3 AVEC LE MASITINIB DANS LE TRAITEMENT DE LA...
AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s Disease
21 nov. 2022 12h09 HE
|
AB Science
PRESS RELEASE AB SCIENCE RECEIVES U.S. FOOD AND DRUG ADMINISTRATION (FDA) AUTHORIZATION TO INITIATE CONFIRMATORY PHASE 3 CLINICAL STUDY WITH MASITINIB IN THE TREATMENT OF ALZHEIMER’S DISEASE Paris,...
DAVOS ALZHEIMER’S COLLABORATIVE ANNOUNCES STRATEGIC PARTNERSHIP WITH THE FINGERS BRAIN HEALTH INSTITUTE AND ITS WORLD-WIDE FINGERS GLOBAL SCIENTIFIC COORDINATING CENTER TO ADVANCE STUDIES ON DELAYING ALZHEIMER’S PROGRESSION
01 nov. 2022 09h00 HE
|
Davos Alzheimer's Collaborative
GENEVA, SWITZERLAND, Nov. 01, 2022 (GLOBE NEWSWIRE) -- The Davos Alzheimer’s Collaborative (DAC), the organization leading an unprecedented global response to Alzheimer’s disease, today announced a...
$8.4 Billion Worldwide Brain Monitoring Industry to 2027 - Increasing Prevalence of Neurodegenerative Diseases is Driving Growth
25 oct. 2022 05h28 HE
|
Research and Markets
Dublin, Oct. 25, 2022 (GLOBE NEWSWIRE) -- The "Brain Monitoring Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...